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Lipoprotein(a) in nephrotic syndrome. Lipoprotein(a) [Lp(a)] is an
independent risk factor for cardiovascular disease, and it has also been
speculated that it promotes thrombosis. Recent studies have shown that
patients with gross proteinuria have greatly increased plasma levels of
Lp(a), but the genesis is obscure. In the present study, plasma Lp(a)
levels were measured in 31 patients with nephrotic syndrome (NS), 24
patients with IgA nephropathy and 43 healthy control subjects. Lp(a)
levels were significantly elevated in NS (median 49.0 mg/dl), in contrast
to the control subjects and patients with IgA nephropathy (median 7.0
and 9.7 mg/dl, respectively). Plasma Lp(a) levels fell markedly in 10 of
10 NS patients after remission. In NS, Lp(a) levels correlated directly
with serum cholesterol levels (P < 0.05) and indirectly with plasma
orosomucoid levels (P < 0.05), but not with serum albumin, triglycer-
ides, HDL cholesterol, urinary protein excretion or GFR. In addition,
Lp(a) tended to be higher in NS patients with edema (median 54.3
mgldl) than in patients without edema (19.0 mg/dl; P = 0.06). Nine NS
patients were further evaluated with plasma ANP levels and urinary
sodium excretion. Plasma Lp(a) correlated directly with ANP (P <
0.01) and indirectly with urinary sodium excretion (P < 0.05). Excellent
correlations were found between Lp(a) and VLDL cholesterol and
VLDL triglycerides, respectively, suggesting a close link between
Lp(a) and triglyceride-rich lipoproteins in nephrosis.
Hyperlipidemia is a common feature of nephrotic syndrome
(NS) and is often included in the definition of the condition [1].
Both increased synthesis and decreased clearance of lipopro-
teins may contribute to the hyperlipidemia usually character-
ized by increases in the total and low-density lipoprotein (LDL)
cholesterol levels, with normal or reduced high-density lipopro-
tein (HDL) cholesterol [2]. In non-nephrotic patients this type
of lipid abnormality is associated with accelerated atheroscle-
rosis [31. Furthermore, a considerably increased incidence of
coronary heart disease has been reported in patients with NS [4,
5].
Lipoprotein(a) [Lp(a)] is a plasma lipoprotein, originally
described by Berg [6], consisting of a particle similar to low-
density lipoprotein (LDL), with apoprotein (a) covalently
linked to apoprotein B-l00 by a disulphide bridge [7]. Plasma
apo(a) levels vary several hundred-fold in the population, and
an inverse relation between the molecular size of apo(a) and its
plasma levels has been found [7]. Moreover, recent studies
have demonstrated that a major part (90%) of the interindi-
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vidual variability is due to genetic factors [8]. In normal
subjects the plasma Lp(a) correlates to the rate of Lp(a)
synthesis rather than to the rate of catabolism [9]. Increased
concentrations of Lp(a) (>30 mg/dl) are associated with an
increased risk of coronary artery disease, similar to and syner-
gistic with increased LDL cholesterol levels [10, 11]. It has also
been proposed that Lp(a) may act as a competitive inhibitor of
plasminogen activation and thus promote thrombosis rather
than fibrinolysis [12—14]. Due to the strong genetic impact,
intraindividual plasma Lp(a) levels are stable. Hitherto only a
few clinical conditions have been found to significantly affect
plasma Lp(a) concentrations [151. It is noteworthy that in-
creased levels of Lp(a) have recently been described in patients
with NS [16—19], but the genesis of this lipid abnormality
remains obscure.
The aim of the present study was to study plasma Lp(a) levels
and their relationship with serum lipid and lipoprotein levels in
patients with NS. In addition we measured 24-hour urinary
protein excretion (UPE), glomerular filtration rate (GFR), mean
arterial blood pressure, plasma orosomucoid and serum albu-
min in the same 31 patients with NS. The presence or absence
of clinically overt edema was also determined. Nine patients
with NS of recent onset were further investigated with respect
to urinary sodium excretion and plasma ANP levels. Further-
more, Lp(a) levels were followed in 10 patients during remis-
sion of NS. A matched group of 24 patients having IgA
nephropathy with only minor urinary protein losses, as well as
10 healthy subjects, served as controls.
Methods
Patients with nephrotic syndrome
A total of 31 adult patients (18 men and 13 women) with NS
seen at the Renal Clinic, Huddinge University Hospital, were
enrolled in the study. Their ethnic origin was Caucasian in 30
cases and Asian in one case. NS was defined as UPE >3.0 g/24
hours and serum albumin 30 g/liter in the presence or absence
of clinically overt edema. Patients with systemic diseases like
diabetes mellitus, rheumatoid arthritis and SLE or massive
obesity (body mass index >34 kg/rn2) were excluded. The
median duration of the NS was eight months (range 1 to 240
months) at the time of examination. Sixteen patients were
taking diuretic agents at the time of examination. Five patients
were on ACE inhibitors, three on beta blockers, two on calcium
antagonists, and two patients were taking lipid-lowering drugs
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Table 1. Histological diagnosis from renal needle biopsy and Lp(a)
concentration in plasma of 31 patients with nephrotic syndrome
Renal pathology N Lp(a) mg/d!
Membranous GN 13 39.7 (20.098.7)°
Focal segmental sclerosis 5 40.1 (36.463.9)°
IgA nephropathy 3 14, 14, 59
Mesangiocapillary GN 3 18, 38, 50
Minimal change GN 3 49, 83, 97
Amyloidosis 2 6 and 78
Mesangioproliferative GN 1 74
Single kidney (not biopsied) 1 41
Total 31 49.0 (19.4—79.0
a Values represent median and quartiles
(simvastatin and gemfibrozil, respectively) at the time of inves-
tigation. Nine patients were on no regular medication. The
presence or absence of clinically overt peripheral edema was
determined at a routine physical examination in all patients. A
renal biopsy had been performed in all except one patient with
a single kidney; Table 1 lists the patients grouped according to
morphological findings. Remission (complete or partial) of the
NS, defined as a decrease in UPE <3 g/24 hr and an increase in
serum albumin >30 g/liter, occurred in 10 patients during the
follow-up (Table 2). In these patients the plasma Lp(a) levels
were reassessed.
All newly diagnosed patients with NS (N = 10) of fairly
recent (median 7 months; range ito 24 months) onset, admitted
to the Renal Clinic at Huddinge University Hospital during the
study period, were asked to participate in further examinations.
These included the plasma lipid profile, plasma ANP, urinary
sodium excretion and GFR. The nine patients who agreed to
participate formed a subgroup of patients with NS (NSsg). All
drugs (diuretics only) were discontinued at least 48 hours prior
to the investigation. The clinical and laboratory characteristics
of these nine patients are presented in Table 3.
Patients with IgA nephropathy
Twenty-four patients having a biopsy-proven IgA nephropa-
thy with UPE <2.5 g124 hr were studied. The group was
selected to match the nephrotic group with respect to age, body
mass index, GFR and mean blood pressure (Table 4). Twelve
patients were taking ACE inhibitors, six patients beta blockers,
five patients diuretics and one patient a calcium antagonist. No
patient was on lipid-lowering drugs, and six patients were not
taking any medication regularly.
Healthy control subjects
Plasma Lp(a) levels were analyzed in a total of 43 healthy
control subjects (C10), none of whom was on any medication. A
subgroup of 10 control subjects (Csg) participated in the same
additional examinations as NSsg.
All patients gave their informed consent and the study was
approved by the Ethics Committee at Huddinge University
Hospital.
Protocol
Throughout the study, patients or control subjects were not
subjected to any dietary restrictions. Blood samples for deter-
minations of cholesterol, triglyceride, HDL-cholesterol, Apo
A1, Apo B, Lp(a), serum albumin and plasma orosomucoid
were drawn from all patients and controls (C8) after they had
fasted overnight. A determination of plasma orosomucoid was
missing in two NS patients. A more detailed lipoprotein analy-
sis was performed, as detailed below, in eight NS patients. The
UPE was determined in all patients with NS and IgA nephrop-
athy, whereas a dipstick test was used to exclude proteinuria in
the controls. In the nephrotic group, GFR was determined with
inulin (N = 9), 51Cr-EDTA (N = 17) or 24-hour creatinine
clearance (N = 4), whereas a clearance determination was
missing in one patient. In the IgA nephropathy group (N 24)
GFR was estimated with 51Cr-EDTA clearance, whereas inulin
clearance was used to estimate GFR in the control group.
Measurements of blood lipids and lipoproteins
The levels of serum cholesterol and triglycerides levels were
analyzed by standard enzymatic procedures (Boehringer Mann-
heim, Mannheim, Germany). HDL-cholesterol levels were de-
termined after precipitation of apo B-containing lipoproteins by
phosphotungstic acid [20]. LDL-cholesterol levels were calcu-
lated using Friedewald's formula [211. In eight cases a more
detailed lipoprotein analysis was performed using a combina-
tion of ultracentrifugation and precipitation [221. Serum sam-
ples (4 ml) were spun at 35,000 rpm for 18 hours at 4°C in a
Centrikon T-2060 ultracentrifuge (Contron Roche, ZUrich,
Switzerland) equipped with a 45.6 rotor. The tubes were sliced
and the floating fraction as well as the infranatant were analyzed
for cholesterol and triglyceride contents. A portion of the
infranatant was treated with phosphotungstic acid to precipitate
apo B-containing lipoproteins. Apolipoproteins A1 and B were
determined using an immunonephelometric procedure (Behring
AG, Marburg, Germany). Lp(a) levels were analyzed using a
commercially available, two-site immunoradiometric assay
(Pharmacia, Uppsala, Sweden). The method uses two mono-
clonal antibodies to different epitopes of apo(a), one labeled
with 125J and one coupled to microsepharose. The coefficient of
variation was 3.8% at a standard concentration of 36.4 mgldl
and 7.2% at a standard concentration of 13.7 mg/dl. The Lp(a)
serum standard was obtained from Immuno AG (Vienna, Aus-
tria).
Other laboratory procedures
The methods of inulin and 51Cr-EDTA clearance were ap-
plied as previously described [23]. Plasma ANP was analyzed
by radioimmunoassay (Milab, Malmö, Sweden) [241. Plasma
orosomucoid levels were measured by a standard immuno-
nephelometric procedure (Behring AG). Determinations of se-
rum albumin, the UPE and urine sodium were carried out in the
Department of Clinical Chemistry, Huddinge Hospital, using
routine methods.
Calculations and statistical analysis
The mean arterial pressure (MAP) was calculated as diastolic
BP + one-third of pulse pressure. The body mass index was
calculated as weight (kg)/height (m)2. The distribution of Lp(a)
was not normally distributed and Lp(a) was therefore given as
medians and quartiles. Also, the duration of NS was not
normally distributed and was therefore given as median and
range. Differences between the groups were assessed using the
two sample non-parametric Mann-Whitney U-test. The
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Table 2. Renal pathology and laboratory characteristics of 10 patients with remission of nephrotic syndrome
No. Renal pathology
UPE g/24 hr Serum aibumin giliter Lp(a) mg/dl
NS Rem. NS Rem.NS Rem.
1 Membranous GN 5.2 2.9 25 32 24 11
2 IgA nephropathy 3.8 <0.1 24 38 14 2
3 Focal segmental sclerosis 14 0.9 15 32 59 30
4 Membranous GN 10,4 2.8 19 37 20 7
5 IgA nephropathy 3.6 1.0 21 41 59 40
6 MembranousGN 5.4 <0.1 25 35 178 110
7 Minimal change GN 13.9 <0.1 13 35 97 17
8 Membranous ON 3.5 1.5 14 38 128 32
9 Minimal change GN 11.9 0.4 14 38 83 63
10 Minimal change GN 10.1 <0.1 8 36 49 10
Abbreviations are: GN, glomerulonephritis; UPE, urinary protein excretion; NS, nephrotic syndrome; Rem., remission.
Table 3. Clinical characteristics in 9 patients with nephrotic syndrome further evaluated with plasma ANP levels and urinary sodium
excretion as compared to 10 controls
No.
Sex
(M/F) Renal pathology Edema
Duration
months Medication
Length of
treatment
Lp(a)
mg/dl
ANP
pmol/!iter
UNa
mmo!/hr
OFR
mi/mm
Nephrotic syndrome
1 M IgA nephropathy Neg. 8 0 0 14 4 17.1 70
2 M Membranous ON Neg. 8 0 0 12 10 23.4 78
3 M Membranous GN Pos. 24 0 0 49 17 10.3 39
4 F Mesangioprolifera-
tive ON
Pos. 7 Furosemide 2 months 74 10 2.4 82
5 F Membranoprolifera-
tive ON
Pos. 19 Furosemide 7 months 38 20 2.3 49
6 M Membranous ON Pos. 5 Furosemide 5 months 172 41 2.5 60
7 M Membranous ON Pos. 1 Amiloride 2 weeks 128 28 4.3 65
8 M Amyloidosis Pos. 1 0 0 78 19 2.7 70
9
Mean SEM
M Minimal change ON Pos. 2
7 (_4)d
0 0 97
74.0 (32.0_104.8)ac
1819 4 5.77.9 2.5 9568 6b
Controls
N = 10 M Neg. None 7.0 (2.5_30.8)c 11 2 13.1 1.5 110 3
a p < 0.01 and b p < 0.001 vs. controls
Values represent median and quartiles
Values represent median and range
Abbreviations are: ANP, atrial natriuretic peptide; UNa, urinary sodium excretion; GFR, glomerular filtration rate; ON, glomerulonephritis.
Wilcoxon signed-rank test was used to test changes in plasma
levels of Lp(a) following remission of NS. The Wald-Wolfowitz
run-test was used to test differences in the cumulative frequen-
cies of plasma Lp(a) and serum cholesterol, respectively, in
NS, IgA nephropathy and C0 groups and also to test differ-
ences in the cumulative frequency of Lp(a) in NS patients with
or without edema. Linear regression analysis was used to
correlate the various parameters shown in Table 6. All data
except Lp(a) are given as means SEM. A two-tailed P value
less than 0.05 was considered to be statistically significant.
Results
Basal clinical data and blood lipids
Basal laboratory data in NS and IgA nephropathy and C
groups are shown in Table 4. The lipid profiles in the three
groups are shown in Table 5. As can be seen the median plasma
level of Lp(a) (49.0 mgldl; quartiles 19.4 to 79.0 mg/dl) in NS
patients was significantly higher than in patients with IgA
nephropathy (median 9.7; quartiles 4.8 to 17.0 mg/dl), C0
(median 7.0; quartiles 2.8 to 26.8 mgldl) and C (median 7.0;
quartiles 2.5 to 30.8 mgldl), respectively. There was no evi-
dence of sex-related differences in the Lp(a) concentration, as
Table 4. Some basal clinical and laboratory findings in Controls (Cg)
and patients with IgA nephropathy or nephrotic syndrome
Controls
(N = 10)
IgA
nephropathy(N = 24)
Nephrotic
syndrome(N = 31)
Age years 33 1 42 2 45 2b
Body mass index kg/rn2 24 1 25 1 25 1
Glomerular filtration rate 110 3 67 5 67 6C
mi/mm
Urinary protein excretion <0.3 g/liter 1.3 0.1 8.8 0,7d
g/24 hr
Serum albumin g/liter 38 1 37 1 19
Mean arterial pressure 86 2 102 2C 102 2C
mm Hg
a p < 0.05, b P < 0.01 and ' P < 0.001 vs. controlsd P < 0.001 vs. IgA nephropathy
the median plasma Lp(a) level was 49.0 mg/dl (quartiles 15.1 to
81.8 mg/dl) in the nephrotic men (N = 18) compared to a median
plasma Lp(a) level of 47.7 mgldl (quartiles 40.6 to 66.0 mg/dl) in
the nephrotic women (N = 13). The cumulative frequencies of
Lp(a) in the NS, IgA nephropathy and C0 groups are shown in
Figure 1. Significant differences in the cumulative frequencies
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groups
Controls
(N = 10)
IgA
nephropathy(N = 24)
Nephrotic
syndrome(N = 31)
S-cholesterol 4.9 0.2 6.9 0,3 10.1 0.5
mmol/liter
S-triglycerides 1.0 0.05 2.0 0.2" 2.8 03c,d
mmol/liter
HDL-Cholesterol 1.3 0.05 1.0 006b 1.5 0.le
mmol/liter
LDL/HDL ratio 2.6 0.2 5.6 0.5" 5.6 0.5"
Apo A1 glliter 1.26 0.06 1.46 0.05a 1.64 0.08
Apo B glliter
Lp(a) mgldl
0.91 0.06
7.0 (2,5_30,8)f
1.45 0.08C
9.7 (4,8_17,o)f
2.40
49.0 (19,4_79,0)b
of Lp(a) were seen between NS patients and both IgA nephrop-
athy patients (P < 0.05) and Cr0, (P < 0.01). Plasma orosomu-
coid, measured in NS patients and Csg only, were significantly
decreased (P < 0.01) in NS (0.59 0.04 g/liter; P < 0.01) as
compared to the 10 healthy subjects (0.71 0,05 glliter). A
significant positive correlation was found between serum albu-
min and plasma orosomucoid (r = 0.44; P < 0.05) in the NS
group.
No significant difference in Lp(a) levels, with respect to the
underlying renal pathology was seen in the NS group (Table 1).
All correlations obtained between the blood lipids and the other
parameters evaluated in the NS group are presented in Table 6.
Lp(a) levels correlated directly with serum cholesterol (r =
0.38; P < 0.05) and indirectly with plasma orosomucoid levels
(r = —0.39; P < 0.05). It is noteworthy that no correlations
were found between Lp(a) and any of the other parameters.
However, the concept that plasma Lp(a) levels may be mostly
influenced by hepatic synthesis prompted us to compare VLDL
and Lp(a) levels in nephrosis. In a subgroup of patients (N = 8)
a more detailed lipoprotein analysis was undertaken. In this
group, Lp(a) correlated significantly with VLDL-cholesterol (r
= 0.92; P < 0.01) and with VLDL-triglycerides (r = 0.92; P <
0.01; Fig. 2).
Lp(a) following remission of the nephrotic syndrome
Ten NS patients had a complete or partial remission of their
disease, following a mean period of 9 2 months. Treatment
with corticosteroids had preceded the remission in five of the
cases. After remission edema disappeared, serum albumin
increased from 18 2 to 36 I glliter, and the median plasma
Lp(a) level fell from 59.0 mg/dl (quartiles 24.0 to 97.0 mgldl) to
23.5 mgldl (quartiles 10.0 to 40.0 mgldl; P < 0.01). Individual
changes in serum albumin and plasma Lp(a) levels are depicted
in Table 2 and Figure 3.
Lp(a), edema and ANP
Serum albumin was lower (17 1 g/liter; P < 0.01) in 22
patients with NS and peripheral edema than in nine patients
without any clinical signs of edema (24 I g/liter). Lower
plasma orosomucoid levels were observed (0.47 0.05 g/liter)
in 20 patients with NS and peripheral edema than in nine NS
patients without any clinical signs of edema (0.71 0.08 g/liter;
P < 0.01). The median plasma Lp(a) level tended to be higher in
the NS group with edema (54.3 mgldl; quartiles 38.2 to 82.6
mg/dl) than in the nine NS patients without clinical edema (19.0
mg/dl; quartiles 14.2 to 49.7 mgldl), although the difference did
not attain statistical significance (P = 0.06; Fig. 4). No signifi-
cant differences between NS patients with or without edema
were observed in mean serum levels of cholesterol or UPE. The
cumulative frequency of serum cholesterol was similar (P =
0.90) in NS patients with or without edema (Fig. 4). A tendency
to higher ANP levels was observed in the NSsg group, as
compared to the Csg group (19 4 vs. 11 2 pmol/liter; P =
0.07). The urinary sodium excretion was 7.9 2.5 mmollhr in
the NSsg as compared to 13.1 1.5 mmollhr in Csg (P = 0.09).
In NSsg, significant correlations were found between Lp(a) and
ANP (r 0.88; P < 0.01) and urinary sodium excretion (r =
—0.67; P < 0.05), respectively (Fig. 5). Multiple regression
analysis confirmed that higher ANP concentrations were asso-
ciated with higher Lp(a) levels, independently of the serum
albumin concentrations and the presence or absence of clinical
edema. However, in view of the genetic impact on Lp(a)
isoforms and plasma levels, these findings in a limited group of
patients will have to be interpreted with caution. No correla-
tions were found in NSg between plasma ANP levels or urinary
sodium excretion and cholesterol, triglycerides, HDL-choles-
terol, Apo A1 and Apo B levels.
Discussion
The present study showed that patients with NS of diverse
etiologies had a significantly higher plasma concentration of
Lp(a) lipoprotein than both a matched group of IgA nephropa-
thy patients with less pronounced proteinuria and a group of
healthy control subjects. The present results thus confirm
previous studies which have demonstrated a major increase in
plasma Lp(a) levels in the nephrotic state [16—19].
The physiologic role and metabolism of Lp(a) is not clear.
The plasma levels of Lp(a) are under the control of the apo(a)
gene to a large extent [7, 8] and are largely unaffected by age,
sex and prandial status [25]. However, the hepatic synthesis
rate appears to be of importance [26] and hormones have been
found to influence Lp(a) levels [27—30]. Based on several
Table S. Mean lipid and apolipoprotein concentrations in the study
a p < 0.05, b p < 0.01 and P < 0.001 vs. controlsd P < 0.05 and e P < 0.001 vs. IgA nephropathy
Values represent median and quartiles
100
80
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40>
20
Lp(a), mg/dl
Fig. I. Cumulative frequency distribution curves of plasma Lp(a)
concentrations in patients with nephrotic syndrome (0), IgA nephrop-
athy (U) and 43 control subjects (C0) (0). Significant changes were
found with the Wald-Wolfowitz run-test between patients with ne-
phrotic syndrome and IgA nephropathy (P < 0.05) and control subjects
(P < 0.01), respectively.
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Table 6. Correlations between lipids and apolipoproteins and GFR, plasma orosomucoid, serum albumin and UPE in 31 patients with
nephrotic syndrome
Serum cholesterol Serum triglycerides Lp(a)
mg/dl
HDL cholesterol
mmol/liter
Apa A1 Apo B
mmollliter giliter
Serum triglycerides mmol/!iter NS
Lp(a) mgldl
HDL cholesterol mmollliter
r = 0.38a
NS
NS
r NS
Apo A1 giliter NS r = NS r = 0.89e
Apo B gluier r = 0.84c r = 0.36a NS NS NS
Glomerular filtration rate mi/mm NS r = NS r = 0.4la NS NS
Plasma orosomucoid gluier r = —0.51k' NS r NS NS NS
Serum albumin gluier
Urinary protein excretion g/24 hr
r = 0.45a
NS
NS
NS
NS
NS
NS
r = r =
NS r =
NS
a p < l P < 0.01 and ' P < 0.001
Abbreviations are: GFR, glomerular filtration rate; UPE, urinary protein excretion; NS, not significant.
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Fig. 2. Correlations between plasma Lp(a) and VLDL-cholesterol (r =
0.92; P <0.01) and VLDL-trigiycerides (r = 0.92; P <0.01) in 8 patients
with nephrotic syndrome.
studies, plasma Lp(a) levels above 30 mg/dI have been consid-
ered an independent risk factor for the development of cardio-
vascular disease in the general population [31, 321. In the
present study 70% of the nephrotic patients had plasma Lp(a)
levels above 30 mgldl, as compared to only 20% of the
(C
0.
-J
Nephrotic syndrome Remission
Fig. 3. Individual changes in serum albumin and plasma Lp(a) levels
in 10 patients with remission of nephrotic syndrome.
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patients with IgA nephropathy and 25% of the healthy con-
trols (Fig. 1). The latter percentage may seem high for Cauca-
sians, but it accords with recent studies reporting that about
25% of the Swedish population has Lp(a) levels above 30 mgldl
[33]. Hitherto, the genesis of the increased levels of plasma
Lp(a) concentration in patients with NS has not been clarified.
In the present study, no correlations between Lp(a) and param-
eters relating to the severity of the NS, such as serum albumin,
UPE or GFR were found. This accords with findings in previous
studies, such as those of Thomas et a! who found no correlation
between Lp(a) and serum albumin levels [17] and Karádi et al
who found no correlation between the Lp(a) concentration and
the degree of urinary protein loss [16].
Only a weak correlation was found between Lp(a) and serum
cholesterol, and no correlation was found between Lp(a) and
Apo B (Table 6). Indeed, an increase in Lp(a) is not an
inevitable consequence of increased serum LDL-cholesterol
concentrations, since primary hypercholesterolemias other
than familial hypercholesterolemia are not conspicuously asso-
ciated with raised Lp(a) values [34], and differing effects on
LDL and Lp(a) have been found in the presence of growth
hormone [35]. The underlying mechanism for both hyperlipid-
emia and increased Lp(a) levels may be multifactorial. In the
present study, we found an excellent correlation between both
VLDL-cholesterol and VLDL-triglycerides and Lp(a) levels,
which may indicate that an increased hepatic synthesis causing
the increase in both lipoproteins may be of importance (Fig. 2).
It is well known that the availability of triglycerides is of major
Urinary sodium, mmo!/hr
Fig. 5. Correlations between plasma Lp(a) and plasma ANP (r = 0.88;
P < 0.01) and hourly urinary sodium excretion (r = —0.67; P < 0.05) in
9 patients with nephrotic syndrome of fairly recent onset.
importance for hepatic lipoprotein secretion [36]. However,
hypertriglyceridemia which is associated with increased VLDL
production does not necessarily result in increases in plasma
Lp(a) levels. It is therefore possible that the complex metabolic
changes in the liver in nephrosis might affect the synthetic rate
of both VLDL and Lp(a) [37]. Further studies are needed to
evaluate these possibilities. At any rate, our findings demon-
strate a close connection between triglyceride-rich lipoproteins
(VLDL) and Lp(a) in nephrosis. Also under normal conditions,
Lp(a) is to some extent associated with triglyceride-rich Ii-
poproteins, and this fraction might be increased in nephrosis
[381. However, the removal rate of VLDL is greatly reduced in
rats with experimentally induced NS, and defective clearance
might therefore contribute to the high levels of VLDL and,
possibly, Lp(a) [39]. The results of studies by Davies et a! [39]
indicate that in NS the defective clearance of chylomicrons and
VLDL is caused by the urinary loss of macromolecules other
than albumin. In this context, our finding of low orosomucoid
levels (reflecting defective synthesis andlor substantial urinary
losses) and a significant inverse correlation between orosomu-
coid and Lp(a) levels in NS patients is of interest. It has been
observed that injection of a1-acid glycoprotein (orosomucoid)
A
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Fig. 4. Cumulative frequency distribution curves of plasma Lp(a) and
serum cholesterol concentrations in nephrotic patients with (0) and
without (•) peripheral edema. With the Wald-Wolfowitz run-test a P
value of 0.06 was found when testing for Lp(a) in the 2 subgroups of
nephrotic patients while a P value of 0.90 was found when testing the
cumulative frequency distribution for serum cholesterol in the 2 sub-
groups of nephrotic patients.
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into nephrotic rats corrects the defect in the removal of triglyc-
eride, which may indicate that orosomucoid is of importance for
the lipid metabolism in NS [40]. Recently reported results of
studies on rat muscle and glomerular capillaries indicate that
orosomucoid is of vital importance for the maintenance of
capillary permselectivity and that decreased levels of orosomu-
coid can be expected to result in an increased transcapillary
passage of macromolecules [41, 42]. Interestingly, the deposi-
tion of Lp(a) in glomeruli has recently been documented in
patients with glonierular disease and proteinuria [43]. In view of
our finding of a significant inverse correlation between oroso-
mucoid and Lp(a) levels, one could, albeit daringly, speculate
that deficient orosomucoid levels may contribute to both eleva-
tion of circulating Lp(a) levels and perhaps also to an increase
in vessel wall Lp(a). However, this question, of course, needs
to be investigated further.
Our observation of significant decreases in plasma Lp(a)
levels after remission of the NS indicates that Lp(a) metabolism
undergoes profound changes during the remission process. This
observation accords with the previous report of lower Lp(a)
levels in eight patients with membranous nephropathy in remis-
sion, as compared to a different group of patients with mem-
branous nephropathy and overt proteinuria [18]. Decreases in
Lp(a) levels following treatment with prednisolone in patients
with NS were reported by Takagoshi et al [19]. In the present
study, we observed similar decreases in Lp(a) levels, irrespec-
tive of treatment with prednisolone, indicating that the fall in
plasma levels of Lp(a) was the result of the correction of some
factor(s) related to the nephrotic state per se rather than an
effect of pharmacological treatment.
The plasma level of Lp(a) in the IgA nephropathy group with
mild renal impairment and moderate, but non-nephrotic, pro-
teinuria was not different from healthy controls, suggesting that
proteinuria in the nephrotic range is essential for the develop-
ment of high plasma Lp(a) levels in glomerular disease. An
elevation of Lp(a) levels in advanced chronic renal disease has
previously been described in patients treated with hemodialy-
sis, peritoneal dialysis or diet [44, 45]. Moreover, high plasma
levels of apo(a) in terminal renal failure patients have been
reported to fall after renal transplantation [46]. All these obser-
vations indicate that advanced renal failure affects the regula-
tion of Lp(a) metabolism. However, the cause of the elevated
Lp(a) levels seen in chronic renal failure is not known. In the
present study, no correlation between the degree of renal
impairment and plasma Lp(a) levels was found, suggesting that
moderate renal impairment, like that observed in our NS and
IgA nephropathy patients, does not influence plasma Lp(a)
levels per Se. Other factors such as uremia, the presence or
absence of nephrotic range proteinuria, other protein losses,
genetic influence or other factors may be more important causes
of elevations of plasma levels of Lp(a) in patients with chronic
renal failure.
In conclusion, the present study confirms that patients with
NS of diverse etiologies have markedly increased plasma level
of Lp(a), in conjunction with other lipid abnormalities. In our
study, the underlying renal pathology or GFR did not affect the
prevailing plasma concentration of Lp(a). Plasma Lp(a) levels
decreased substantially in all NS patients who experienced
remission of the NS. In addition, the present study also
demonstrates a relationship between VLDL and orosomucoid
levels and the plasma levels of Lp(a) in NS.
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Appendix. Abbreviations
Lp(a) — Lipoprotein(a)NS — Nephrotic syndrome
NS19 — A subgroup of patients with nephrotic syndrome
C10, — The total control group
Csg — A subgroup of controls
UPE — Urinary protein excretion
ANP — Atrial natriuretic peptide
GN — Glomerulonephritis
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